{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-002460","form_type":"8-K","ticker":"VACH","cik":"0002006815","company_name":"Voyager Acquisition Corp./Cayman Islands","filed_at":"2026-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.974804+00:00","generated_at":"2026-05-15T09:58:25.864041+00:00","sec_items":["5.07","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Voyager Acquisition shareholders approve Veraxa Biotech deal; 99.67% of Class A shares redeemed","bullets":["Shareholders approved business combination with Veraxa Biotech AG at March 12, 2026 meeting.","25,217,315 Class A shares redeemed (~99.67%), leaving ~$885,556 in trust account.","After closing, combined company to trade on Nasdaq as VRXA.","Remaining 82,685 Class A shares will convert into Veraxa Biotech Holding AG shares.","Closing subject to Nasdaq listing approvals and other customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-002460","json":"https://secwatch.observer/filing/0001829126-26-002460.json","markdown":"https://secwatch.observer/filing/0001829126-26-002460.md","text":"https://secwatch.observer/filing/0001829126-26-002460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2006815/000182912626002460/0001829126-26-002460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2006815/000182912626002460/voyageracq_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:58:25.864041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}